MENS: Jyong Biotech Corp Operating Margin

Corporate emblem and logo of Jyong Biotech Ltd (MENS)

Changes in the core business margin demonstrate current dynamics, where this metric equals 0.00. Jyong Biotech Ltd (MENS) faces risks associated with a limited development pipeline and pending FDA verdicts. Growth is driven by an aging population and the potential for mergers within the urology sector. Efficiency is based on the synthesis of phytotherapy and Western standards, creating unique treatment methods for men's health.

MENS - jyongbio.com Operating Profit Rate over the range 06/18/2025 - 11/20/2026

MENS (jyongbio.com): analytical breakdowns and indicator data

Fundamental company analysis:Jyong Biotech
Finished products of Jyong Biotech Ltd

The assessment of Jyong Biotech Ltd (MENS) margin of safety is based on the operating margin, which measures the efficiency of profit generation from core activities before accounting for financial obligations and taxes. Analyzing the operating margin curve allows for tracking the impact of development costs for men's health drugs, confirming the resilience of the business model amid the diversification of research into cancer and prostate adenoma.

Direct competitors

Operating Profitability haleon.com|Operating Profitability KVUE|Operating Profitability Verona Pharma (VRNA)|Ligand Pharmaceuticals - Return on Sales by Operating Profit|Operating Profitability Amneal AMRX|Operating Profitability Margin Perrigo Company PLC|Alvotech Biopharmaceuticals - Operating Margin|Profitability of Operations Liquidia Technologies LQDA|Galapagos N.V. (GLPG) - Operating Profitability|anipharmaceuticals.com - Operating Profit Rate|Operating Sales Margin MNKD|AMPH: Operating Profit Rate|Operating Profitability pacira.com (PCRX)|Operating Margin ARS Pharma (SPRY)|Theravance Biopharma - Operating Sales Margin|Operating Profit Ratio AQST (Aquestive Therapeutics)|SCPH: Operating Sales Margin|Operating Return on Sales Tectonic Therapeutic|TNXP: Operating Margin|SXT China (SXTC) - Operating Margin|Operating Profitability eupraxiapharma.com|BioHarvest Sciences (BHST) - Profitability of Operations|Operating Profitability Invizyne (EXOZ)|ORMP - Operating Return on Sales|Operating Margin ENTX (Entera Bio)|Operating Profitability Margin MindWalk Therapeutics|ABVC: Operating Sales Margin|CPIX - Operating Margin|QNTM (Quantum BioPharma) - Operating Sales Margin|Operating Profit Margin FGEN (FibroGen)|TELO (Telomir Pharmaceuticals Corp) - Operating Margin|Operating Margin ranitherapeutics.com|Operating Profitability Synergy CHC Corp. (SNYR)|Rallybio Corp - Return on Sales by Operating Profit|lexariabioscience.com - Operating Sales Margin|Operating Margin Pulmatrix Inc PULM|Pheton Holdings - Operating Margin|Operating Profit Margin APM|Lyra Therapeutics, Inc. (LYRA) - Operating Profitability|Operating Return on Sales Impact BioMedical, Inc. (IBO)|Operating Profitability TNF Pharma|YCBD: Operating Profit Rate|Operating Margin PRFX|CYTO - Operating Return on Sales|Operating Profitability Lipella LIPO|Operating Profit Ratio OPTN (OptiNose, Inc.)|PIRS - Operating Profitability|Procaps (PROC) - Operating Sales Margin|PTPI: Operating Margin|Qilian International (QLI) - Operating Margin|Operating Profitability Acelyrin, Inc.|Operating Margin TFF Pharmaceuticals, Inc.